INTRODUCTION: Yaws, caused by Treponema pallidum ssp. pertenue, is endemic in parts of West Africa, Southeast Asia and the Pacific. The WHO has launched a campaign based on mass treatment with azithromycin, to eradicate yaws by 2020.
SOURCES OF DATA: We reviewed published data, surveillance data and data presented at yaws eradication meetings.
AREAS OF AGREEMENT: Azithromycin is now the preferred agent for treating yaws. Point-of-care tests have demonstrated their value in yaws.
AREAS OF CONTROVERSY: There is limited data from 76 countries, which previously reported yaws. Different doses of azithromycin are used in community mass treatment for yaws and trachoma.
GROWING POINTS: Yaws eradication appears an achievable goal. The programme will require considerable support from partners across health and development sectors.
AREAS TIMELY FOR DEVELOPING RESEARCH: Studies to complete baseline mapping, integrate diagnostic tests into surveillance and assess the impact of community mass treatment with azithromycin are ongoing.
BT - British medical bulletin C1 -http://www.ncbi.nlm.nih.gov/pubmed/25525120?dopt=Abstract
DO - 10.1093/bmb/ldu037 IS - 1 J2 - Br. Med. Bull. LA - eng M3 - review N2 -INTRODUCTION: Yaws, caused by Treponema pallidum ssp. pertenue, is endemic in parts of West Africa, Southeast Asia and the Pacific. The WHO has launched a campaign based on mass treatment with azithromycin, to eradicate yaws by 2020.
SOURCES OF DATA: We reviewed published data, surveillance data and data presented at yaws eradication meetings.
AREAS OF AGREEMENT: Azithromycin is now the preferred agent for treating yaws. Point-of-care tests have demonstrated their value in yaws.
AREAS OF CONTROVERSY: There is limited data from 76 countries, which previously reported yaws. Different doses of azithromycin are used in community mass treatment for yaws and trachoma.
GROWING POINTS: Yaws eradication appears an achievable goal. The programme will require considerable support from partners across health and development sectors.
AREAS TIMELY FOR DEVELOPING RESEARCH: Studies to complete baseline mapping, integrate diagnostic tests into surveillance and assess the impact of community mass treatment with azithromycin are ongoing.
PY - 2015 SP - 91 EP - 100 T2 - British medical bulletin TI - Yaws. UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350436/ VL - 113 SN - 1471-8391 ER -